|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Molecular Genetics |
Radiation Therapy Oncology Group (RTOG) Translational Research Program, Philadelphia, PA: Departments of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322 (D.J.B.); RTOG Statistical Division, Philadelphia, PA 19107 (W.F.S.); Division of Neuropathology, Washington University School of Medicine, St. Louis, MO 63110 (A.P.); Department of Pathology, LDS Hospital, Salt Lake City, UT 84143 (E.H.H.); Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226 (K.J.M.); Department of Radiation Oncology, SUNY Health Sciences Center, Brooklyn, NY 11203 (A.R.S.); Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792 (M.P.M.); Department of Radiation Oncology, Jefferson Medical College, Philadelphia, PA 19107 (W.J.C.); USA
2 Address correspondence to Daniel J. Brat, Department of Pathology and Laboratory Medicine, Emory University Hospital H-176, 1364 Clifton Road NE, Atlanta, GA 30322 (dbrat{at}emory.edu).
Abstract
Survival periods vary considerably for patients with high-grade astrocytomas, and reliable prognostic markers are not currently available. We therefore investigated whether genetic losses from chromosomes 1p, 19q, 9p, or 10q were associated with survival in 89 high-grade astrocytomas using tissue microarrays (TMAs) derived from Radiation Therapy Oncology Group clinical trials. Cases included 15 anaplastic astrocytomas (AAs) and 74 glioblastomas (GBMs) selected on the basis of survival times significantly shorter or longer than the expected median. Genetic analysis was performed by TMA-fluorescence in situ hybridization (FISH) on array sections using 8 DNA probes, including those directed at 1p32, 19q13.4, 9p21 (p16/CDKN2A), and 10q (PTEN and DMBT1). Genetic status for each locus was correlated with patient survival group, and data were analyzed by using Fisher's exact test of association (adjusted P = 0.025). Losses of chromosome 1p, either alone or in combination with 19q, were encountered in only 2 cases, both AAs. This contrasts with oligodendrogliomas, in which combined 1p and 19q losses are frequent and predictive of prolonged survival. Solitary 19q loss was noted in 3/15 AAs and in 7/70 GBMs and was more frequent in the long-term survival group (P = 0.041, AA and GBM combined). Chromosome 9p loss was seen in 5/8 AAs and 39/57 GBMs, whereas chromosome 10q loss was detected in 4/15 AAs and 48/68 GBMs. The 9p and 10q deletions were slightly more frequent in short-term survivors, though none of the comparisons achieved statistical significance. Long-term and short-term survival groups of high-grade astrocytomas appear to have dissimilar frequencies of 19q, 9p, and 10q deletions. TMA-FISH is a rapid and efficient way of evaluating genetic alterations in such tumors.
References
Balesaria, S., Brock, C., Bower, M., Clark, J., Nicholson, S.K., Lewis, P., de Sanctis, S., Evans, H., Peterson, D., Mendoza, N., Glaser, M.G., Newlands, E.S., and Fisher, R.A. (1999) Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br. J. Cancer 81,1371 -1377.[CrossRef][Web of Science][Medline]
Brat, D.J., Castellano-Sanchez, A., Kaur, B., and Van Meir, E.G. (2002) Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 9,24 -36.[CrossRef][Web of Science][Medline]
Burton, E.C., Lamborn, K.R., Feuerstein, B.G., Prados, M., Scott,
J., Forsyth, P., Passe, S., Jenkins, R.B., and Aldape, K.D.
(2002) Genetic aberrations defined by comparative genomic
hybridization distinguish long-term from typical survivors of glioblastoma.
Cancer Res. 62,6205
-6210.
CBTRUS. Central Brain Tumor Registry of the United States (2002) Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Chicago, Ill.: Central Brain Tumor Registry of the United States.
Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K.,
Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R.,
Ino, Y., Ramsay, D.A., and Louis, D.N. (1998) Specific genetic
predictors of chemotherapeutic response and survival in patients with
anaplastic oligodendrogliomas. J. Natl. Cancer Inst.
90,1473
-1479.
Cavenee, W.K., Furnari, F.B., Nagane, M., Huang, H.-J.S., Newcombe, E.W., Bigner, D.D., Weller, M., Berens, M.E., Plate, K.H., Israel, M.A., Noble, M.D., and Kleihues, P. (2000) Diffusely infiltrating astrocytomas. In Kleihues, P., and Cavenee, W.K., eds. Pathology and Genetics of Tumours of the Nervous System. 2nd ed. (Kleihues, P., and Sobin, L.H., series eds. World Health Organization Classification of Tumors), pp. 10-21. Lyon: IARC Press.
Curran, W.J., Jr., Scott, C.B., Horton, J., Nelson, J.S.,
Weinstein, A.S., Fischbach, A.J., Chang, C.H., Rotman, M., Asbell, S.O., and
Krisch, R.E. (1993a) Recursive partitioning analysis of
prognostic factors in three Radiation Therapy Oncology Group malignant glioma
trials. J. Natl. Cancer Inst.
85,704
-710.
Curran, W.J., Jr., Scott, C.B., Weinstein, A.S., Martin, L.A.,
Nelson, J.S., Phillips, T.L., Murray, K., Fischbach, A.J., Yakar, D., and
Schwade, J.G. (1993b) Survival comparison of
radiosurgery-eligible and -ineligible malignant glioma patients treated with
hyperfractionated radiation therapy and carmustine: A report of Radiation
Therapy Oncology Group 83-02. J. Clin. Oncol.
11,857
-862.
Fujisawa, H., Kurrer, M., Reis, R.M., Yonekawa, Y., Kleihues, P.,
and Ohgaki, H. (1999) Acquisition of the glioblastoma phenotype
during astrocytoma progression is associated with loss of heterozygosity on
10q25qter. Am. J. Pathol.
155,387
-394.
Fuller, C.E., and Perry, A. (2002) Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol. 12,67 -86.[Web of Science][Medline]
Fuller, C.E., Wang, H., Zhang, W., Fuller, G.N., and Perry, A. (2002) High-throughput molecular profiling of high-grade astrocytomas: The utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J. Neuropathol. Exp. Neurol. 61,1078 -1084.[Web of Science][Medline]
Ganju, V., Jenkins, R.B., O'Fallon, J.R., Scheithauer, B.W., Ransom, D.T., Katzmann, J.A., and Kimmel, D.W. (1994) Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 74,920 -927.[CrossRef][Web of Science][Medline]
Hunter, S.B., Brat, D.J., Olson, J.J., von Deimling, A., Zhou, W., and Van Meir, E.G. (2003) Alterations in molecular pathways of diffusely infiltrating glial neoplasms: Application to tumor classification and anti-tumor therapy. Int. J. Oncol. 23,857 -869.[Web of Science][Medline]
Ino, Y., Zlatescu, M.C., Sasaki, H., Macdonald, D.R., Stemmer-Rachamimov, A.O., Jhung, S., Ramsay, D.A., von Deimling, A., Louis, D.N., and Cairncross, J.G. (2002) Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J. Neurosurg. 92,983 -990.
Kamiryo, T., Tada, K., Shiraishi, S., Shinojima, N., Nakamura, H., Kochi, M., Kuratsu, J., Saya, H., and Ushio, Y. (2002) Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J. Neurosurg. 96,815 -822.[CrossRef][Web of Science][Medline]
Kraus, J.A., Glesmann, N., Beck, M., Krex, D., Klockgether, T., Schackert, G., and Schlegel, U. (2000) Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neurooncol. 48, 89-94.[CrossRef][Medline]
Kunwar, S., Mohapatra, G., Bollen, A., Lamborn, K.R., Prados, M.,
and Feuerstein, B.G. (2001) Genetic subgroups of anaplastic
astrocytomas correlate with patient age and survival. Cancer
Res. 61,7683
-7688.
Kurup, P.D., Pajak, T.F., Hendrickson, F.R., Nelson, J.S., Mansell, J., Cohen, L., Awschalom, M., Rosenberg, I., and Ten Haken, R.K. (1985) Fast neutrons and misonidazole for malignant astrocytomas. Int. J. Radiat. Oncol. Biol. Phys. 11,679 -686.[Web of Science][Medline]
Maruno, M., Yoshimine, T., Muhammad, A.K., Tokiyoshi, K., and Hayakawa, T. (1996) Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications. J. Neurooncol. 30,19 -24.[Medline]
Nelson, D.F., Diener-West, M., Weinstein, A.S., Schoenfeld, D., Nelson, J.S., Sause, W.T., Chang, C.H., Goodman, R., and Carabell, S. (1986) A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study. Int. J. Radiat. Oncol. Biol. Phys. 12,1793 -1800.[Web of Science][Medline]
Nelson, D.F., Diener-West, M., Horton, J., Chang, C.H., Schoenfeld, D., and Nelson, J.S. (1988) Combined modality approach to treatment of malignant gliomas—re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 6, 279-284.
Perry, A., Tonk, V., McIntire, D.D., and White, C.L., 3rd (1997a) Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival, formalin-fixed, paraffin-embedded tissue and nonfluorescent light microscopy. Am. J. Clin. Pathol. 108,166 -174.[Web of Science][Medline]
Perry, A., Nobori, T., Ru, N., Anderl, K., Borell, T.J., Mohapatra, G., Feuerstein, B.G., Jenkins, R.B., and Carson, D.A. (1997b) Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J. Neuropathol. Exp. Neurol. 56,999 -1008.[Web of Science][Medline]
Perry, A., Anderl, K., Borell, T.J., Kimmel, D.W., Wang, C.H., O'Fallon, J.R., Feuerstein, B.G., Scheithauer, B.W., and Jenkins, R.B. (1999) Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am. J. Clin. Pathol. 112,801 -809.[Web of Science][Medline]
Perry, A., Fuller, C.E., Banerjee, R., Brat, D.J., and Scheithauer, B.W. (2003) Ancillary FISH analysis for 1p and 19q status: Preliminary observations in 287 gliomas and oligodendroglioma mimics. Front. Biosci. 8,a1 -a9.[Web of Science][Medline]
RTOG. Radiation Therapy Oncology Group (2003) Protocols available at http://www.rtog.org.
Schmidt, M.C., Antweiler, S., Urban, N., Mueller, W., Kuklik, A., Meyer-Puttlitz, B., Wiestler, O.D., Louis, D.N., Fimmers, R., and von Deimling, A. (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol. Exp. Neurol. 61,321 -328.[Web of Science][Medline]
Smith, J.S., Perry, A., Borell, T.J., Lee, H.K., O'Fallon, J.,
Hosek, S.M., Kimmel, D., Yates, A., Burger, P.C., Scheithauer, B.W., and
Jenkins, R.B. (2000) Alterations of chromosome arms 1p and 19q as
predictors of survival in oligodendrogliomas, astrocytomas, and mixed
oligoastrocytomas. J. Clin. Oncol.
18,636
-645.
Smith, J.S., Tachibana, I., Passe, S.M., Huntley, B.K., Borell,
T.J., Iturria, N., O'Fallon, J.R., Schaefer, P.L., Scheithauer, B.W., James,
C.D., Buckner, J.C., and Jenkins, R.B. (2001) PTEN mutation, EGFR
amplification, and outcome in patients with anaplastic astrocytoma and
glioblastoma multiforme. J. Natl. Cancer Inst.
93,1246
-1256.
Steck, P.A., Lin, H., Langford, L.A., Jasser, S.A., Koul, D., Yung, W.K., and Pershouse, M.A. (1999) Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 24,135 -143.[CrossRef][Web of Science][Medline]
Tada, K., Shiraishi, S., Kamiryo, T., Nakamura, H., Hirano, H., Kuratsu, J., Kochi, M., Saya, H., and Ushio, Y. (2001) Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival. J. Neurosurg. 95,651 -659.[Web of Science][Medline]
Zhou, X.P., Li, Y.J., Hoang-Xuan, K., Laurent-Puig, P., Mokhtari, K., Longy, M., Sanson, M., Delattre, J.Y., Thomas, G., and Hamelin, R. (1999) Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations. Int. J. Cancer. 84,150 -154.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Hitoshi, B. T. Harris, H. Liu, B. Popko, and M. A. Israel Spinal Glioma: Platelet-Derived Growth Factor B-Mediated Oncogenesis in the Spinal Cord Cancer Res., October 15, 2008; 68(20): 8507 - 8515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al. Long-term survival with glioblastoma multiforme Brain, October 1, 2007; 130(10): 2596 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Miller, C. P. Dunham, B. W. Scheithauer, and A. Perry Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas J. Clin. Oncol., December 1, 2006; 24(34): 5419 - 5426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Liu, P. J. Park, W. Lai, E. Maher, A. Chakravarti, L. Durso, X. Jiang, Y. Yu, A. Brosius, M. Thomas, et al. A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in Glioblastoma Cancer Res., November 15, 2006; 66(22): 10815 - 10823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
